Clinical Trials
6 trialsNCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT02346370 2019-02-08
PRIMAL
Halozyme Therapeutics
Phase 1 Terminated
NCT00454779 2018-10-17
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Amgen
Phase 2 Completed
NCT01794845 2017-05-11
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
University of Miami
Phase 2 Terminated
NCT00095199 2012-10-15
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed